<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="13" family="AdvPSMy-B" color="#ffffff"/>
	<fontspec id="font1" size="25" family="AdvPSMy-B" color="#25408e"/>
	<fontspec id="font2" size="9" family="AdvPSMy-B" color="#000000"/>
	<fontspec id="font3" size="9" family="AdvC2866" color="#000000"/>
	<fontspec id="font4" size="9" family="AdvC2867" color="#000000"/>
	<fontspec id="font5" size="8" family="AdvC2866" color="#000000"/>
	<fontspec id="font6" size="8" family="AdvC2867" color="#000000"/>
	<fontspec id="font7" size="8" family="AdvTimes" color="#000000"/>
	<fontspec id="font8" size="11" family="AdvPSMySB" color="#000000"/>
	<fontspec id="font9" size="8" family="AdvP4C4E74" color="#000000"/>
	<fontspec id="font10" size="7" family="AdvPSMy-R" color="#000000"/>
	<fontspec id="font11" size="9" family="AdvP641C" color="#000000"/>
	<fontspec id="font12" size="7" family="AdvPSMy-B" color="#000000"/>
	<fontspec id="font13" size="7" family="AdvPSSym,Italic" color="#000000"/>
	<fontspec id="font14" size="8" family="AdvPSMy-R" color="#000000"/>
	<fontspec id="font15" size="15" family="AdvC2866" color="#000000"/>
	<fontspec id="font16" size="8" family="AdvPSMy-B" color="#b21f24"/>
<text top="50" left="45" width="67" height="12" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title">Perspective</text>
<text top="72" left="45" width="366" height="23" font="font1" id="p1_t2" reading_order_no="3" segment_no="2" tag_type="title">ADAPT: The Wrong Way to Stop</text>
<text top="102" left="45" width="160" height="23" font="font1" id="p1_t3" reading_order_no="4" segment_no="2" tag_type="title">a Clinical Trial</text>
<text top="131" left="45" width="69" height="8" font="font2" id="p1_t4" reading_order_no="5" segment_no="3" tag_type="text">Steven E. Nissen</text>
<text top="155" left="45" width="156" height="8" font="font3" id="p1_t5" reading_order_no="6" segment_no="5" tag_type="text">In an accompanying article published</text>
<text top="166" left="45" width="8" height="8" font="font3" id="p1_t6" reading_order_no="7" segment_no="5" tag_type="text">in</text>
<text top="166" left="57" width="75" height="8" font="font4" id="p1_t7" reading_order_no="8" segment_no="5" tag_type="text">PLoS Clinical Trials</text>
<text top="166" left="132" width="69" height="8" font="font3" id="p1_t8" reading_order_no="9" segment_no="5" tag_type="text">, the Alzheimer’s</text>
<text top="177" left="45" width="156" height="8" font="font3" id="p1_t9" reading_order_no="10" segment_no="5" tag_type="text">Disease Anti-Inﬂammatory Prevention</text>
<text top="188" left="45" width="156" height="8" font="font3" id="p1_t10" reading_order_no="11" segment_no="5" tag_type="text">Trial (ADAPT) Research Group report</text>
<text top="199" left="45" width="156" height="8" font="font3" id="p1_t11" reading_order_no="12" segment_no="5" tag_type="text">the cardiovascular outcomes from their</text>
<text top="211" left="45" width="156" height="8" font="font3" id="p1_t12" reading_order_no="13" segment_no="5" tag_type="text">study [1]. The circumstances surround-</text>
<text top="222" left="45" width="156" height="8" font="font3" id="p1_t13" reading_order_no="14" segment_no="5" tag_type="text">ing the termination of ADAPT were</text>
<text top="233" left="45" width="156" height="8" font="font3" id="p1_t14" reading_order_no="15" segment_no="5" tag_type="text">unusual and provide an important</text>
<text top="244" left="45" width="156" height="8" font="font3" id="p1_t15" reading_order_no="16" segment_no="5" tag_type="text">lesson for all clinical trialists, demon-</text>
<text top="255" left="45" width="156" height="8" font="font3" id="p1_t16" reading_order_no="17" segment_no="5" tag_type="text">strating the importance of following</text>
<text top="266" left="45" width="156" height="8" font="font3" id="p1_t17" reading_order_no="18" segment_no="5" tag_type="text">rigorous procedures for prematurely</text>
<text top="277" left="45" width="156" height="8" font="font3" id="p1_t18" reading_order_no="19" segment_no="5" tag_type="text">stopping clinical trials. In this case,</text>
<text top="288" left="45" width="156" height="8" font="font3" id="p1_t19" reading_order_no="20" segment_no="5" tag_type="text">stopping the trial before its intended</text>
<text top="299" left="45" width="156" height="8" font="font3" id="p1_t20" reading_order_no="21" segment_no="5" tag_type="text">completion resulted in data that can-</text>
<text top="311" left="45" width="109" height="8" font="font3" id="p1_t21" reading_order_no="22" segment_no="5" tag_type="text">not be reliably interpreted.</text>
<text top="322" left="54" width="147" height="8" font="font5" id="p1_t22" reading_order_no="23" segment_no="8" tag_type="text">On September 30, 2004, Merck with-</text>
<text top="332" left="45" width="156" height="8" font="font5" id="p1_t23" reading_order_no="24" segment_no="8" tag_type="text">drew rofecoxib (Vioxx) from the market</text>
<text top="343" left="45" width="156" height="8" font="font5" id="p1_t24" reading_order_no="25" segment_no="8" tag_type="text">after the trial’s data safety and monitor-</text>
<text top="353" left="45" width="156" height="8" font="font5" id="p1_t25" reading_order_no="26" segment_no="8" tag_type="text">ing board (DSMB) recommended termi-</text>
<text top="364" left="45" width="156" height="8" font="font5" id="p1_t26" reading_order_no="27" segment_no="8" tag_type="text">nation of a placebo-controlled study of</text>
<text top="374" left="45" width="156" height="8" font="font5" id="p1_t27" reading_order_no="28" segment_no="8" tag_type="text">this agent in the prevention of colon</text>
<text top="385" left="45" width="156" height="8" font="font5" id="p1_t28" reading_order_no="29" segment_no="8" tag_type="text">polyps [2]. The reason for study termi-</text>
<text top="396" left="45" width="156" height="8" font="font5" id="p1_t29" reading_order_no="30" segment_no="8" tag_type="text">nation was a statistically signiﬁcant in-</text>
<text top="406" left="45" width="156" height="8" font="font5" id="p1_t30" reading_order_no="31" segment_no="8" tag_type="text">c r e a s e i n a d v e r s e c a r d i o v a s c u l a r</text>
<text top="417" left="45" width="156" height="8" font="font5" id="p1_t31" reading_order_no="32" segment_no="8" tag_type="text">outcomes. On December 17, 2004, Pﬁzer</text>
<text top="427" left="45" width="156" height="8" font="font5" id="p1_t32" reading_order_no="33" segment_no="8" tag_type="text">announced that termination of a trial of</text>
<text top="438" left="45" width="156" height="8" font="font5" id="p1_t33" reading_order_no="34" segment_no="8" tag_type="text">celecoxib (Celebrex) in colon polyp pre-</text>
<text top="449" left="45" width="156" height="8" font="font5" id="p1_t34" reading_order_no="35" segment_no="8" tag_type="text">vention, because it also showed statisti-</text>
<text top="459" left="45" width="156" height="8" font="font5" id="p1_t35" reading_order_no="36" segment_no="8" tag_type="text">cally signiﬁcant evidence for increased</text>
<text top="470" left="45" width="156" height="8" font="font5" id="p1_t36" reading_order_no="37" segment_no="8" tag_type="text">cardiovascular event rates [3]. The results</text>
<text top="480" left="45" width="156" height="8" font="font5" id="p1_t37" reading_order_no="38" segment_no="8" tag_type="text">of these two trials were subsequently</text>
<text top="491" left="45" width="137" height="8" font="font5" id="p1_t38" reading_order_no="39" segment_no="8" tag_type="text">published in February 2005 in the</text>
<text top="491" left="187" width="14" height="8" font="font6" id="p1_t39" reading_order_no="40" segment_no="8" tag_type="text">New</text>
<text top="502" left="45" width="110" height="8" font="font6" id="p1_t40" reading_order_no="41" segment_no="8" tag_type="text">England Journal of Medicine</text>
<text top="502" left="161" width="40" height="8" font="font5" id="p1_t41" reading_order_no="42" segment_no="8" tag_type="text">[4,5]. The</text>
<text top="512" left="45" width="156" height="8" font="font5" id="p1_t42" reading_order_no="43" segment_no="8" tag_type="text">revelations about increased cardiovascu-</text>
<text top="523" left="45" width="80" height="8" font="font5" id="p1_t43" reading_order_no="44" segment_no="8" tag_type="text">lar events with these</text>
<text top="522" left="128" width="4" height="8" font="font7" id="p1_t44" reading_order_no="45" segment_no="8" tag_type="text">‘‘</text>
<text top="523" left="132" width="24" height="8" font="font5" id="p1_t45" reading_order_no="46" segment_no="8" tag_type="text">coxibs</text>
<text top="522" left="156" width="4" height="8" font="font7" id="p1_t46" reading_order_no="47" segment_no="8" tag_type="text">’’</text>
<text top="523" left="164" width="37" height="8" font="font5" id="p1_t47" reading_order_no="48" segment_no="8" tag_type="text">generated</text>
<text top="533" left="45" width="156" height="8" font="font5" id="p1_t48" reading_order_no="49" segment_no="8" tag_type="text">enormous public attention and concern.</text>
<text top="544" left="45" width="156" height="8" font="font5" id="p1_t49" reading_order_no="50" segment_no="8" tag_type="text">However, in both cases, the decision-</text>
<text top="555" left="45" width="156" height="8" font="font5" id="p1_t50" reading_order_no="51" segment_no="8" tag_type="text">making leading to trial discontinuation</text>
<text top="565" left="45" width="156" height="8" font="font5" id="p1_t51" reading_order_no="52" segment_no="8" tag_type="text">was handled appropriately through the</text>
<text top="576" left="45" width="156" height="8" font="font5" id="p1_t52" reading_order_no="53" segment_no="8" tag_type="text">regular reviews conducted by an inde-</text>
<text top="586" left="45" width="60" height="8" font="font5" id="p1_t53" reading_order_no="54" segment_no="8" tag_type="text">pendent DSMB.</text>
<text top="597" left="54" width="147" height="8" font="font5" id="p1_t54" reading_order_no="55" segment_no="16" tag_type="text">Three days following the announcement</text>
<text top="608" left="45" width="156" height="8" font="font5" id="p1_t55" reading_order_no="56" segment_no="16" tag_type="text">of the termination of the celecoxib colon</text>
<text top="618" left="45" width="156" height="8" font="font5" id="p1_t56" reading_order_no="57" segment_no="16" tag_type="text">polyp prevention study, the National</text>
<text top="629" left="45" width="156" height="8" font="font5" id="p1_t57" reading_order_no="58" segment_no="16" tag_type="text">Institute of Health (NIH), issued a press</text>
<text top="639" left="45" width="63" height="8" font="font5" id="p1_t58" reading_order_no="59" segment_no="16" tag_type="text">release entitled</text>
<text top="639" left="114" width="4" height="8" font="font7" id="p1_t59" reading_order_no="60" segment_no="16" tag_type="text">‘‘</text>
<text top="639" left="119" width="82" height="8" font="font5" id="p1_t60" reading_order_no="61" segment_no="16" tag_type="text">Use of Non-Steroid</text>
<text top="650" left="45" width="156" height="8" font="font5" id="p1_t61" reading_order_no="62" segment_no="16" tag_type="text">Anti-Inﬂammatory Drugs Suspended in</text>
<text top="661" left="45" width="156" height="8" font="font5" id="p1_t62" reading_order_no="63" segment_no="16" tag_type="text">Large Alzheimer’s Disease Prevention</text>
<text top="671" left="45" width="18" height="8" font="font5" id="p1_t63" reading_order_no="64" segment_no="16" tag_type="text">Trial</text>
<text top="671" left="63" width="4" height="8" font="font7" id="p1_t64" reading_order_no="65" segment_no="16" tag_type="text">’’</text>
<text top="671" left="72" width="129" height="8" font="font5" id="p1_t65" reading_order_no="66" segment_no="16" tag_type="text">[6]. The NIH press release stated</text>
<text top="155" left="219" width="15" height="8" font="font5" id="p1_t66" reading_order_no="67" segment_no="4" tag_type="text">that</text>
<text top="154" left="239" width="4" height="8" font="font7" id="p1_t67" reading_order_no="68" segment_no="4" tag_type="text">‘‘</text>
<text top="155" left="243" width="132" height="8" font="font5" id="p1_t68" reading_order_no="69" segment_no="4" tag_type="text">data from the ADAPT trial indi-</text>
<text top="165" left="219" width="156" height="8" font="font5" id="p1_t69" reading_order_no="70" segment_no="4" tag_type="text">cated an apparent increase in cardiovas-</text>
<text top="176" left="219" width="156" height="8" font="font5" id="p1_t70" reading_order_no="71" segment_no="4" tag_type="text">cular and cerebrovascular events among</text>
<text top="186" left="219" width="156" height="8" font="font5" id="p1_t71" reading_order_no="72" segment_no="4" tag_type="text">participants taking naproxen when com-</text>
<text top="197" left="219" width="69" height="8" font="font5" id="p1_t72" reading_order_no="73" segment_no="4" tag_type="text">pared to placebo.</text>
<text top="196" left="288" width="4" height="8" font="font7" id="p1_t73" reading_order_no="74" segment_no="4" tag_type="text">’’</text>
<text top="197" left="296" width="79" height="8" font="font5" id="p1_t74" reading_order_no="75" segment_no="4" tag_type="text">In the press release,</text>
<text top="207" left="219" width="156" height="8" font="font5" id="p1_t75" reading_order_no="76" segment_no="4" tag_type="text">NIH Director Dr. Elias Zerhouni stated</text>
<text top="218" left="219" width="15" height="8" font="font5" id="p1_t76" reading_order_no="77" segment_no="4" tag_type="text">that</text>
<text top="217" left="237" width="4" height="8" font="font7" id="p1_t77" reading_order_no="78" segment_no="4" tag_type="text">‘‘</text>
<text top="218" left="241" width="134" height="8" font="font5" id="p1_t78" reading_order_no="79" segment_no="4" tag_type="text">this step is being taken as a precau-</text>
<text top="228" left="219" width="156" height="8" font="font5" id="p1_t79" reading_order_no="80" segment_no="4" tag_type="text">tionary measure to ensure the safety of</text>
<text top="239" left="219" width="92" height="8" font="font5" id="p1_t80" reading_order_no="81" segment_no="4" tag_type="text">the study’s participants</text>
<text top="238" left="311" width="4" height="8" font="font7" id="p1_t81" reading_order_no="82" segment_no="4" tag_type="text">’’</text>
<text top="239" left="320" width="34" height="8" font="font5" id="p1_t82" reading_order_no="83" segment_no="4" tag_type="text">and that</text>
<text top="238" left="359" width="4" height="8" font="font7" id="p1_t83" reading_order_no="84" segment_no="4" tag_type="text">‘‘</text>
<text top="239" left="363" width="12" height="8" font="font5" id="p1_t84" reading_order_no="85" segment_no="4" tag_type="text">the</text>
<text top="249" left="219" width="156" height="8" font="font5" id="p1_t85" reading_order_no="86" segment_no="4" tag_type="text">investigators made their decision based</text>
<text top="260" left="219" width="156" height="8" font="font5" id="p1_t86" reading_order_no="87" segment_no="4" tag_type="text">on the risk/beneﬁt analysis speciﬁc to this</text>
<text top="270" left="219" width="18" height="8" font="font5" id="p1_t87" reading_order_no="88" segment_no="4" tag_type="text">trial.</text>
<text top="270" left="237" width="4" height="8" font="font7" id="p1_t88" reading_order_no="89" segment_no="4" tag_type="text">’’</text>
<text top="270" left="247" width="128" height="8" font="font5" id="p1_t89" reading_order_no="90" segment_no="4" tag_type="text">Shortly following the NIH an-</text>
<text top="281" left="219" width="156" height="8" font="font5" id="p1_t90" reading_order_no="91" segment_no="4" tag_type="text">nouncement, the Food and Drug Admin-</text>
<text top="291" left="219" width="156" height="8" font="font5" id="p1_t91" reading_order_no="92" segment_no="4" tag_type="text">istration (FDA) issued a public statement</text>
<text top="302" left="219" width="15" height="8" font="font5" id="p1_t92" reading_order_no="93" segment_no="4" tag_type="text">that</text>
<text top="301" left="240" width="4" height="8" font="font7" id="p1_t93" reading_order_no="94" segment_no="4" tag_type="text">‘‘</text>
<text top="302" left="244" width="131" height="8" font="font5" id="p1_t94" reading_order_no="95" segment_no="4" tag_type="text">based on emerging information</text>
<text top="312" left="219" width="156" height="8" font="font5" id="p1_t95" reading_order_no="96" segment_no="4" tag_type="text">from a long-term prevention trial, the</text>
<text top="323" left="219" width="156" height="8" font="font5" id="p1_t96" reading_order_no="97" segment_no="4" tag_type="text">risk of cardiovascular and cerebrovascu-</text>
<text top="333" left="219" width="156" height="8" font="font5" id="p1_t97" reading_order_no="98" segment_no="4" tag_type="text">lar events may increase among patients</text>
<text top="344" left="219" width="62" height="8" font="font5" id="p1_t98" reading_order_no="99" segment_no="4" tag_type="text">taking naproxen</text>
<text top="343" left="281" width="4" height="8" font="font7" id="p1_t99" reading_order_no="100" segment_no="4" tag_type="text">’’</text>
<text top="344" left="288" width="11" height="8" font="font5" id="p1_t100" reading_order_no="101" segment_no="4" tag_type="text">[7].</text>
<text top="354" left="228" width="147" height="8" font="font5" id="p1_t101" reading_order_no="102" segment_no="9" tag_type="text">These announcements generated</text>
<text top="365" left="219" width="108" height="8" font="font5" id="p1_t102" reading_order_no="103" segment_no="9" tag_type="text">front-page headlines such as</text>
<text top="364" left="330" width="4" height="8" font="font7" id="p1_t103" reading_order_no="104" segment_no="9" tag_type="text">‘‘</text>
<text top="365" left="334" width="41" height="8" font="font5" id="p1_t104" reading_order_no="105" segment_no="9" tag_type="text">Heart Risk</text>
<text top="375" left="219" width="72" height="8" font="font5" id="p1_t105" reading_order_no="106" segment_no="9" tag_type="text">Seen in Naproxen</text>
<text top="375" left="291" width="4" height="8" font="font7" id="p1_t106" reading_order_no="107" segment_no="9" tag_type="text">’’</text>
<text top="375" left="300" width="3" height="8" font="font5" id="p1_t107" reading_order_no="108" segment_no="9" tag_type="text">(</text>
<text top="375" left="302" width="68" height="8" font="font6" id="p1_t108" reading_order_no="109" segment_no="9" tag_type="text">Wall Street Journal</text>
<text top="375" left="370" width="4" height="8" font="font5" id="p1_t109" reading_order_no="110" segment_no="9" tag_type="text">),</text>
<text top="385" left="219" width="4" height="8" font="font7" id="p1_t110" reading_order_no="111" segment_no="9" tag_type="text">‘‘</text>
<text top="386" left="223" width="110" height="8" font="font5" id="p1_t111" reading_order_no="112" segment_no="9" tag_type="text">Tough Choice: Pain or Risk</text>
<text top="385" left="333" width="4" height="8" font="font7" id="p1_t112" reading_order_no="113" segment_no="9" tag_type="text">’’</text>
<text top="386" left="341" width="3" height="8" font="font5" id="p1_t113" reading_order_no="114" segment_no="9" tag_type="text">(</text>
<text top="386" left="344" width="31" height="8" font="font6" id="p1_t114" reading_order_no="115" segment_no="9" tag_type="text">USA To-</text>
<text top="396" left="219" width="11" height="8" font="font6" id="p1_t115" reading_order_no="116" segment_no="9" tag_type="text">day</text>
<text top="396" left="230" width="21" height="8" font="font5" id="p1_t116" reading_order_no="117" segment_no="9" tag_type="text">), and</text>
<text top="396" left="254" width="4" height="8" font="font7" id="p1_t117" reading_order_no="118" segment_no="9" tag_type="text">‘‘</text>
<text top="396" left="258" width="117" height="8" font="font5" id="p1_t118" reading_order_no="119" segment_no="9" tag_type="text">Patients, Doctors Agonize over</text>
<text top="407" left="219" width="76" height="8" font="font5" id="p1_t119" reading_order_no="120" segment_no="9" tag_type="text">Risks of Painkiller (</text>
<text top="407" left="295" width="63" height="8" font="font6" id="p1_t120" reading_order_no="121" segment_no="9" tag_type="text">Los Angeles Times</text>
<text top="407" left="358" width="17" height="8" font="font5" id="p1_t121" reading_order_no="122" segment_no="9" tag_type="text">) [8].</text>
<text top="417" left="219" width="156" height="8" font="font5" id="p1_t122" reading_order_no="123" segment_no="9" tag_type="text">Occurring immediately following the rev-</text>
<text top="428" left="219" width="156" height="8" font="font5" id="p1_t123" reading_order_no="124" segment_no="9" tag_type="text">elations about rofecoxib and celecoxib,</text>
<text top="438" left="219" width="156" height="8" font="font5" id="p1_t124" reading_order_no="125" segment_no="9" tag_type="text">the naproxen announcement generated</text>
<text top="449" left="219" width="156" height="8" font="font5" id="p1_t125" reading_order_no="126" segment_no="9" tag_type="text">considerable public apprehension [8].</text>
<text top="459" left="219" width="156" height="8" font="font5" id="p1_t126" reading_order_no="127" segment_no="9" tag_type="text">Physicians received many urgent calls</text>
<text top="470" left="219" width="156" height="8" font="font5" id="p1_t127" reading_order_no="128" segment_no="9" tag_type="text">from worried patients. However, there</text>
<text top="480" left="219" width="156" height="8" font="font5" id="p1_t128" reading_order_no="129" segment_no="9" tag_type="text">was a major problem with the naproxen</text>
<text top="491" left="219" width="156" height="8" font="font5" id="p1_t129" reading_order_no="130" segment_no="9" tag_type="text">warning: it was not based upon the</text>
<text top="501" left="219" width="156" height="8" font="font5" id="p1_t130" reading_order_no="131" segment_no="9" tag_type="text">application of standard procedures for</text>
<text top="512" left="219" width="156" height="8" font="font5" id="p1_t131" reading_order_no="132" segment_no="9" tag_type="text">stopping an ongoing clinical trial. During</text>
<text top="522" left="219" width="156" height="8" font="font5" id="p1_t132" reading_order_no="133" segment_no="9" tag_type="text">the subsequent FDA hearings to set policy</text>
<text top="533" left="219" width="156" height="8" font="font5" id="p1_t133" reading_order_no="134" segment_no="9" tag_type="text">on nonsteroidal anti-inﬂammatory agents</text>
<text top="543" left="219" width="156" height="8" font="font5" id="p1_t134" reading_order_no="135" segment_no="9" tag_type="text">(NSAIDs) and COX-2 inhibitors, I de-</text>
<text top="554" left="219" width="156" height="8" font="font5" id="p1_t135" reading_order_no="136" segment_no="9" tag_type="text">scribed the warnings about naproxen as</text>
<text top="564" left="219" width="4" height="8" font="font7" id="p1_t136" reading_order_no="137" segment_no="9" tag_type="text">‘‘</text>
<text top="564" left="223" width="152" height="8" font="font5" id="p1_t137" reading_order_no="138" segment_no="9" tag_type="text">the medical equivalent of yelling ‘ﬁre’ in</text>
<text top="575" left="219" width="84" height="8" font="font5" id="p1_t138" reading_order_no="139" segment_no="9" tag_type="text">a crowded auditorium</text>
<text top="574" left="303" width="4" height="8" font="font7" id="p1_t139" reading_order_no="140" segment_no="9" tag_type="text">’’</text>
<text top="575" left="310" width="11" height="8" font="font5" id="p1_t140" reading_order_no="141" segment_no="9" tag_type="text">[9].</text>
<text top="592" left="219" width="125" height="11" font="font8" id="p1_t141" reading_order_no="142" segment_no="15" tag_type="title">The Data Finally Become</text>
<text top="604" left="219" width="46" height="11" font="font8" id="p1_t142" reading_order_no="143" segment_no="15" tag_type="title">Available</text>
<text top="624" left="218" width="157" height="8" font="font5" id="p1_t143" reading_order_no="144" segment_no="18" tag_type="text">Now, nearly two years after the closure of</text>
<text top="635" left="219" width="156" height="8" font="font5" id="p1_t144" reading_order_no="145" segment_no="18" tag_type="text">the ADAPT study, we ﬁnally get to see the</text>
<text top="645" left="219" width="156" height="8" font="font5" id="p1_t145" reading_order_no="146" segment_no="18" tag_type="text">data that resulted in the public warning</text>
<text top="656" left="219" width="156" height="8" font="font5" id="p1_t146" reading_order_no="147" segment_no="18" tag_type="text">about naproxen [1]. For the standard</text>
<text top="666" left="219" width="156" height="8" font="font5" id="p1_t147" reading_order_no="148" segment_no="18" tag_type="text">composite endpoint of cardiovascular</text>
<text top="677" left="219" width="156" height="8" font="font5" id="p1_t148" reading_order_no="149" segment_no="18" tag_type="text">death, myocardial infarction, and stroke,</text>
<text top="687" left="219" width="156" height="8" font="font5" id="p1_t149" reading_order_no="150" segment_no="18" tag_type="text">there were 17 events in celecoxib treat-</text>
<text top="698" left="219" width="156" height="8" font="font5" id="p1_t150" reading_order_no="151" segment_no="18" tag_type="text">ment group, 23 in the naproxen arm, and</text>
<text top="708" left="219" width="156" height="8" font="font5" id="p1_t151" reading_order_no="152" segment_no="18" tag_type="text">22 in the placebo. The hazard ratio for</text>
<text top="719" left="219" width="156" height="8" font="font5" id="p1_t152" reading_order_no="153" segment_no="18" tag_type="text">naproxen compared with placebo was</text>
<text top="155" left="393" width="156" height="8" font="font5" id="p1_t153" reading_order_no="154" segment_no="6" tag_type="text">1.57 with 95% conﬁdence intervals of</text>
<text top="165" left="393" width="46" height="8" font="font5" id="p1_t154" reading_order_no="155" segment_no="6" tag_type="text">0.87 to 2.81,</text>
<text top="166" left="443" width="4" height="8" font="font6" id="p1_t155" reading_order_no="156" segment_no="6" tag_type="text">p</text>
<text top="165" left="449" width="7" height="8" font="font9" id="p1_t156" reading_order_no="157" segment_no="6" tag_type="text">¼</text>
<text top="165" left="458" width="91" height="8" font="font5" id="p1_t157" reading_order_no="158" segment_no="6" tag_type="text">0.13. A broader compo-</text>
<text top="176" left="393" width="156" height="8" font="font5" id="p1_t158" reading_order_no="159" segment_no="6" tag_type="text">site outcome that added heart failure and</text>
<text top="187" left="393" width="156" height="8" font="font5" id="p1_t159" reading_order_no="160" segment_no="6" tag_type="text">transient ischemic attack yielded a mar-</text>
<text top="198" left="393" width="67" height="8" font="font5" id="p1_t160" reading_order_no="161" segment_no="6" tag_type="text">ginally signiﬁcant</text>
<text top="198" left="463" width="4" height="8" font="font6" id="p1_t161" reading_order_no="162" segment_no="6" tag_type="text">p</text>
<text top="198" left="471" width="78" height="8" font="font5" id="p1_t162" reading_order_no="163" segment_no="6" tag_type="text">value when compar-</text>
<text top="209" left="393" width="104" height="8" font="font5" id="p1_t163" reading_order_no="164" segment_no="6" tag_type="text">ing naproxen with placebo.</text>
<text top="220" left="402" width="147" height="8" font="font5" id="p1_t164" reading_order_no="165" segment_no="7" tag_type="text">We must ask whether a DSMB would</text>
<text top="230" left="393" width="156" height="8" font="font5" id="p1_t165" reading_order_no="166" segment_no="7" tag_type="text">stop an ongoing clinical trial for such</text>
<text top="241" left="393" width="156" height="8" font="font5" id="p1_t166" reading_order_no="167" segment_no="7" tag_type="text">ﬁndings. The answer, it appears, was that</text>
<text top="252" left="393" width="156" height="8" font="font5" id="p1_t167" reading_order_no="168" segment_no="7" tag_type="text">the DSMB did not stop the trial; NIH</text>
<text top="263" left="393" width="156" height="8" font="font5" id="p1_t168" reading_order_no="169" segment_no="7" tag_type="text">ofﬁcials did [8]. There was no regularly</text>
<text top="273" left="393" width="156" height="8" font="font5" id="p1_t169" reading_order_no="170" segment_no="7" tag_type="text">scheduled DSMB safety review that re-</text>
<text top="284" left="393" width="156" height="8" font="font5" id="p1_t170" reading_order_no="171" segment_no="7" tag_type="text">sulted in study termination. It appears</text>
<text top="295" left="393" width="156" height="8" font="font5" id="p1_t171" reading_order_no="172" segment_no="7" tag_type="text">that NIH ofﬁcials, concerned about rev-</text>
<text top="306" left="393" width="156" height="8" font="font5" id="p1_t172" reading_order_no="173" segment_no="7" tag_type="text">elations regarding the safety of coxibs in</text>
<text top="317" left="393" width="156" height="8" font="font5" id="p1_t173" reading_order_no="174" segment_no="7" tag_type="text">the colon polyps studies, simply decided</text>
<text top="327" left="393" width="156" height="8" font="font5" id="p1_t174" reading_order_no="175" segment_no="7" tag_type="text">to look at the cardiovascular event results</text>
<text top="338" left="393" width="156" height="8" font="font5" id="p1_t175" reading_order_no="176" segment_no="7" tag_type="text">in ADAPT [8,10]). Seeing a marginally</text>
<text top="349" left="393" width="156" height="8" font="font5" id="p1_t176" reading_order_no="177" segment_no="7" tag_type="text">signiﬁcant difference between naproxen</text>
<text top="360" left="393" width="156" height="8" font="font5" id="p1_t177" reading_order_no="178" segment_no="7" tag_type="text">and placebo, they abruptly stopped the</text>
<text top="370" left="393" width="156" height="8" font="font5" id="p1_t178" reading_order_no="179" segment_no="7" tag_type="text">trial. Indeed, NIH ofﬁcials went even</text>
<text top="381" left="393" width="156" height="8" font="font5" id="p1_t179" reading_order_no="180" segment_no="7" tag_type="text">further and issued the public warning [6].</text>
<text top="392" left="402" width="147" height="8" font="font5" id="p1_t180" reading_order_no="181" segment_no="10" tag_type="text">Both the termination of this trial and</text>
<text top="403" left="393" width="156" height="8" font="font5" id="p1_t181" reading_order_no="182" segment_no="10" tag_type="text">the issuance of a public warning about</text>
<text top="414" left="393" width="156" height="8" font="font5" id="p1_t182" reading_order_no="183" segment_no="10" tag_type="text">naproxen were inappropriate and re-</text>
<text top="425" left="393" width="156" height="8" font="font5" id="p1_t183" reading_order_no="184" segment_no="10" tag_type="text">ﬂected faulty logic. These actions un-</text>
<text top="435" left="393" width="156" height="8" font="font5" id="p1_t184" reading_order_no="185" segment_no="10" tag_type="text">necessarily created public consternation</text>
<text top="696" left="45" width="156" height="6" font="font10" id="p1_t185" reading_order_no="222" segment_no="20" tag_type="text">The Perspectives section is for experts to discuss the</text>
<text top="704" left="45" width="147" height="6" font="font10" id="p1_t186" reading_order_no="223" segment_no="20" tag_type="text">clinical practice or public health implications of a</text>
<text top="712" left="45" width="137" height="6" font="font10" id="p1_t187" reading_order_no="224" segment_no="20" tag_type="text">published study that is freely available online.</text>
<text top="459" left="393" width="156" height="8" font="font11" id="p1_t188" reading_order_no="186" segment_no="11" tag_type="text">.........................................................</text>
<text top="472" left="393" width="28" height="6" font="font12" id="p1_t189" reading_order_no="187" segment_no="12" tag_type="text">Funding:</text>
<text top="472" left="423" width="126" height="6" font="font10" id="p1_t190" reading_order_no="188" segment_no="12" tag_type="text">The author received no specific funding for</text>
<text top="480" left="393" width="32" height="6" font="font10" id="p1_t191" reading_order_no="189" segment_no="12" tag_type="text">this article.</text>
<text top="494" left="393" width="66" height="6" font="font12" id="p1_t192" reading_order_no="190" segment_no="13" tag_type="text">Competing Interests:</text>
<text top="494" left="461" width="58" height="6" font="font10" id="p1_t193" reading_order_no="191" segment_no="13" tag_type="text">SEN is the principal</text>
<text top="502" left="393" width="137" height="6" font="font10" id="p1_t194" reading_order_no="192" segment_no="13" tag_type="text">investigator for a large clinical trial comparing</text>
<text top="510" left="393" width="156" height="6" font="font10" id="p1_t195" reading_order_no="193" segment_no="13" tag_type="text">cardiovascular event rates for three nonsteroidal anti-</text>
<text top="518" left="393" width="140" height="6" font="font10" id="p1_t196" reading_order_no="194" segment_no="13" tag_type="text">inflammatory agents: naproxen, ibuprofen, and</text>
<text top="526" left="393" width="156" height="6" font="font10" id="p1_t197" reading_order_no="195" segment_no="13" tag_type="text">celecoxib. Although the study is supported by Pfizer,</text>
<text top="534" left="393" width="154" height="6" font="font10" id="p1_t198" reading_order_no="196" segment_no="13" tag_type="text">SEN and the Executive Committee for the trial have</text>
<text top="542" left="393" width="147" height="6" font="font10" id="p1_t199" reading_order_no="197" segment_no="13" tag_type="text">stipulated that no member of the trial leadership</text>
<text top="550" left="393" width="154" height="6" font="font10" id="p1_t200" reading_order_no="198" segment_no="13" tag_type="text">may accept any compensation from the sponsor or</text>
<text top="558" left="393" width="114" height="6" font="font10" id="p1_t201" reading_order_no="199" segment_no="13" tag_type="text">any other maker of drugs in this class.</text>
<text top="572" left="393" width="27" height="6" font="font12" id="p1_t202" reading_order_no="200" segment_no="14" tag_type="text">Citation:</text>
<text top="572" left="422" width="127" height="6" font="font10" id="p1_t203" reading_order_no="201" segment_no="14" tag_type="text">Nissen SE (2006) ADAPT: The wrong way to</text>
<text top="580" left="393" width="132" height="6" font="font10" id="p1_t204" reading_order_no="202" segment_no="14" tag_type="text">stop a clinical trial. PLoS Clin Trials 1(7): e35.</text>
<text top="588" left="393" width="96" height="6" font="font10" id="p1_t205" reading_order_no="203" segment_no="14" tag_type="text">doi:10.1371/journal.pctr.0010035</text>
<text top="602" left="393" width="33" height="6" font="font12" id="p1_t206" reading_order_no="204" segment_no="17" tag_type="text">Copyright:</text>
<text top="602" left="428" width="6" height="7" font="font13" id="p1_t207" reading_order_no="205" segment_no="17" tag_type="text"><i>Ó</i></text>
<text top="602" left="435" width="114" height="6" font="font10" id="p1_t208" reading_order_no="206" segment_no="17" tag_type="text">2006 Steven E. Nissen. This is an open-</text>
<text top="610" left="393" width="144" height="6" font="font10" id="p1_t209" reading_order_no="207" segment_no="17" tag_type="text">access article distributed under the terms of the</text>
<text top="618" left="393" width="136" height="6" font="font10" id="p1_t210" reading_order_no="208" segment_no="17" tag_type="text">Creative Commons Attribution License, which</text>
<text top="626" left="393" width="125" height="6" font="font10" id="p1_t211" reading_order_no="209" segment_no="17" tag_type="text">permits unrestricted use, distribution, and</text>
<text top="634" left="393" width="152" height="6" font="font10" id="p1_t212" reading_order_no="210" segment_no="17" tag_type="text">reproduction in any medium, provided the original</text>
<text top="642" left="393" width="94" height="6" font="font10" id="p1_t213" reading_order_no="211" segment_no="17" tag_type="text">author and source are credited.</text>
<text top="656" left="393" width="46" height="6" font="font12" id="p1_t214" reading_order_no="212" segment_no="19" tag_type="text">Abbreviations:</text>
<text top="656" left="441" width="99" height="6" font="font10" id="p1_t215" reading_order_no="213" segment_no="19" tag_type="text">ADAPT, Alzheimer’s Disease Anti-</text>
<text top="664" left="393" width="156" height="6" font="font10" id="p1_t216" reading_order_no="214" segment_no="19" tag_type="text">Inflammatory Prevention Trial; DSMB, data safety and</text>
<text top="672" left="393" width="118" height="6" font="font10" id="p1_t217" reading_order_no="215" segment_no="19" tag_type="text">monitoring board; FDA, Food and Drug</text>
<text top="680" left="393" width="147" height="6" font="font10" id="p1_t218" reading_order_no="216" segment_no="19" tag_type="text">Administration; NIH, National Institutes of Health;</text>
<text top="688" left="393" width="133" height="6" font="font10" id="p1_t219" reading_order_no="217" segment_no="19" tag_type="text">NSAID, nonsteroidal anti-inflammatory agent</text>
<text top="696" left="393" width="144" height="6" font="font10" id="p1_t220" reading_order_no="218" segment_no="19" tag_type="text">Steven Nissen is chairman of the Department of</text>
<text top="704" left="393" width="141" height="6" font="font10" id="p1_t221" reading_order_no="219" segment_no="19" tag_type="text">Cardiovascular Medicine at the Cleveland Clinic</text>
<text top="712" left="393" width="151" height="6" font="font10" id="p1_t222" reading_order_no="220" segment_no="19" tag_type="text">Foundation, Cleveland, Ohio, United States. E-mail:</text>
<text top="720" left="393" width="46" height="6" font="font10" id="p1_t223" reading_order_no="221" segment_no="19" tag_type="text">nissens@ccf.org</text>
<text top="742" left="45" width="85" height="7" font="font14" id="p1_t224" reading_order_no="225" segment_no="21" tag_type="text">www.plosclinicaltrials.org</text>
<text top="742" left="471" width="78" height="7" font="font14" id="p1_t225" reading_order_no="227" segment_no="22" tag_type="text">November | 2006 | e35</text>
<text top="742" left="289" width="16" height="7" font="font14" id="p1_t226" reading_order_no="226" segment_no="23" tag_type="text">0001</text>
<text top="26" left="459" width="28" height="14" font="font15" id="p1_t227" reading_order_no="0" segment_no="0" tag_type="title">PLoS</text>
<text top="30" left="489" width="60" height="7" font="font16" id="p1_t228" reading_order_no="1" segment_no="0" tag_type="title">CLINICAL TRIALS</text>
</page>
</pdf2xml>
